Best Practice & Research Clinical Endocrinology & Metabolism
Volume 21, Issue 3 , Pages 462-478, September 2007

Environment, testicular dysgenesis and carcinoma in situ testis

University Department of Growth & Reproduction, Rigshospitalet, Blegdamsvej 9, DK-2100 Copenhagen, Denmark

The testicular dysgenesis syndrome (TDS) hypothesis proposes that a proportion of the male reproductive disorders–cryptorchidism, hypospadias, infertility and testicular cancer–may be symptoms of one underlying developmental disease, TDS, which is most likely a result of disturbed gonadal development in the embryo. TDS may be caused by genetic factors, environmental/life-style factors, or a combination of both. Some rare disorders of sex development of genetic origin are among the best-known examples of severe TDS. Among the environmental and life-style factors that are suspected to influence the hormonal milieu of the developing gonad are the endocrine disrupters. A prenatal exposure to commonly used chemicals, e.g. phthalates, may result in a TDS-like phenotype in rats. Currently, this animal model is the best model for TDS. In humans the situation is much more complex, and TDS exists in a wide range of phenotypes: from the mildest and most common form, in which impaired spermatogenesis is the only symptom, to the most severe cases, in which the patient may develop testicular cancer. It is of great importance that clinicians in different specialties treating patients with TDS are aware of the association between the different symptoms.

Key words: testicular dysgenesis syndrome, TDS, testicular cancer, intratubular germ cell neoplasia, IGCN, carcinoma in situ testis, CIS, male fertility, cryptorchidism, hypospadias, endocrine disruptors, anti-androgens, estrogens

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1521-690X(07)00032-2

doi:10.1016/j.beem.2007.04.002

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 21, Issue 3 , Pages 462-478, September 2007